Medicines360, a non-profit women’s health pharmaceutical company, and Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360’s New Drug Application (NDA) for Levosert™ (levonorgestrel), a hormonal intrauterine contraceptive (IUC) for use by women to prevent pregnancy.
Medicines360, a non-profit pharmaceutical company, and Actavis, Inc., a leading global specialty pharmaceutical company, today announced a historic partnership to support Medicines360’s mission to reduce cost as a barrier to accessing women’s birth control. The Medicines360 and Actavis partnership will make the IUD available in the U.S. commercially and at a very low price in U.S.public sector clinics. As part of this agreement, Actavis has licensed the U.S. commercial rights for the Medicines360 LNG20 Intrauterine Device (IUD).
Collaboration to Develop State-of-the-Art Levonorgestrel Releasing Intrauterine Device (LNG IUD) As Highly Effective Long-acting Reversible Contraceptive
Medicines360, the US-based non-profit that addresses unmet medical needs of women and children by developing innovative, affordable and sustainable medical solutions, today announced a strategic partnership with European women’s health pharmaceutical company Uteron Pharma Operations (UPO), based in Liege Belgium, to develop a long-acting LNG IUD. As part of the collaborative agreement, Uteron is responsible for the design and manufacture of the product, and Medicines360 is responsible for Phase III clinical development.
Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg
Strategic alliance will increase engagement with U.S. public health clinics and their patients about hormonal IUDs (long-acting reversible contraceptives, or LARCs) SAN FRANCISCO and CHARLESTON, S.C. – Medicines360 and Afaxys Pharma, LLC, two mission-driven, socially conscious women’s health pharmaceutical companies, today announced their collaboration to promote Medicines360’s intrauterine system (IUS), LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg, which is […]
Medicines360, the non-profit pharmaceutical company behind the hormonal IUD Liletta, is on a mission to increase women’s access to reproductive care around the world. This month, the female-led company announced the launch of Avibela, a hormonal IUD, in Madagascar.
Partnership will provide free hormonal IUDs to underserved women across the country SAN FRANCISCO and SANTA BARBARA, Calif. – Medicines360, a mission-driven women’s health pharmaceutical nonprofit and Direct Relief, a humanitarian aid organization, today announced their partnership to provide Medicines360’s hormonal IUD, LILETTA®, free of charge to clinics that serve the most vulnerable women in the United States, […]